ACHN up +4.15% percent Today $ACHN High is at 14.35 and the

New Post Public Reply Private Reply Replies (0) Message Board

Nov 14, 2014 at 1:36 PM

ACHN up +4.15% percent Today $ACHN High is at 14.35 and the Low 13.51 with current volume of 2,382,305.

Recent News posted below.

Achillion Pharmaceuticals ACHN other info.
http://investorshangout.com/Achillion-Pharmac...CHN-53213/

ACHN Achillion Pharmaceuticals Recent Headline News

Nasdaq stocks posting largest percentage increases
AP - Thu Nov 13, 5:05PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
ESCA: 13.28 (-0.24), IMDZ: 35.80 (-0.17), OLED: 27.50 (+0.30), FUEL: 18.54 (-0.66), CZR: 16.88 (+0.37), NTIC: 20.00 (-0.75), RESN: 7.19 (unch), OREX: 5.63 (-0.23), VBFC: 22.00 (+0.95), FLML: 12.86 (-0.53), ACHN: 13.79 (+0.30), RDI: 11.98 (unch), AMOT: 18.95 (-0.32), SUSQ: 13.08 (+0.02), RDIB: 12.00 (-0.04)

Profit taking sinks Achillion
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 12:48PM CST

ACHN: 13.79 (+0.30)

5 Momentum Stocks Currently on the Move with More Potential Upside
at The Street - Thu Nov 13, 11:34AM CST
Achillion, Groupon, Orexigen, Rackspace and TG Therapeutics have had strong recent moves and are showing no sign of slowing.
OREX: 5.63 (-0.23), RAX: 43.83 (+0.50), ACHN: 13.79 (+0.30), TGTX: 14.01 (+0.14), GRPN: 7.83 (+0.06)

Will Achillion Pharmaceuticals (ACHN) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 6:25AM CST
Will Achillion Pharmaceuticals (ACHN) Continue to Surge Higher?
ACHN: 13.79 (+0.30)

Achillion Pharmaceuticals: Still Bullish, But Taking Profits
Dr. Paul Nunzio DeSantis, Pharm.D - Seeking Alpha - Wed Nov 12, 4:06PM CST
By Dr. Paul Nunzio De Santis (Pharm.D.) Entry: $9.86 10/2/14 Take Profits: $14.45 11/12/14 Hold 10-20% of profits into event for M&A upside. Achillion (NASDAQ: ACHN ) has been a stellar performer since we wrote about it on October 2nd- up...
ACHN: 13.79 (+0.30), MRK: 58.97 (-0.57), ABBV: 63.75 (+0.12)

Achillion Pharmaceuticals (ACHN) Stock Rises on Positive Hepatitis C Drug Results
at The Street - Wed Nov 12, 10:57AM CST
Shares of Achillion Pharmaceuticals (ACHN) continued to rise Wednesday after the company reported encouraging interim results from a Phase II study of its hepatitis C drug ACH-3102.
ACHN: 13.79 (+0.30)

Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 12, 7:48AM CST
Companies like AbbVie (ABBV), Gilead (GILD) and Achillion (ACHN) had a strong presence at the annual Liver Meeting.
VRTX: 112.26 (-0.46), GILD: 102.01 (-2.19), ACHN: 13.79 (+0.30), DNDN: 0.12 (-0.01), AMGN: 157.53 (-3.32), ABBV: 63.75 (+0.12), REGN: 396.11 (-6.52)

This Tiny Biotech Is Piggybacking on Gilead Sciences, Inc.'s Success
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 7:43AM CST
Source: Gilead Sciences. Developing drugs that help established blockbusters work better is a major trend in biotechnology. It's a lower-stakes game because drug developers only need to show that their products can improve upon existing therapies,...
GILD: 102.01 (-2.19), ACHN: 13.79 (+0.30), MRK: 58.97 (-0.57)

Most active Nasdaq-traded stocks
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
FB: 74.63 (+0.38), ACHN: 13.79 (+0.30), DNDN: 0.12 (-0.01), CMCSK: 53.80 (-0.23), ARCP: 8.70 (-0.11), ZNGA: 2.71 (-0.02), MSFT: 49.60 (-0.01), INTC: 33.89 (+0.21), GRPN: 7.83 (+0.06), CMCSA: 53.96 (-0.34), AAPL: 113.95 (+1.13), CSCO: 26.20 (+0.52)

Achillion Jumps on Encouraging Data on its HCV Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 4:10PM CST
Shares of Achillion Pharmaceuticals (ACHN) soared over 27% after the company reported encouraging interim results on ACH-3102.
JNJ: 108.26 (-0.81), GILD: 101.99 (-2.21), ACHN: 13.79 (+0.30), AMAG: 33.95 (-0.29)

Why Is Gilead Always Holding The Ace? A Prediction Of The Future HCV Market And What Analysts Aren't Talking About
Pharma Doc - Seeking Alpha - Tue Nov 11, 10:13AM CST
No matter when you've followed Gilead (NASDAQ: GILD ) over the past decade, they always seem to be holding the ace. Whether in the HIV arena or now in HCV, the Gilead management is always one step ahead and is planning to dominate its market. Gilead...
GILD: 101.99 (-2.21), ACHN: 13.79 (+0.30), MRK: 58.97 (-0.57), ABBV: 63.75 (+0.12), BMY: 57.84 (+0.04)

Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:03AM CST

JNJ: 108.26 (-0.81), GILD: 101.99 (-2.21), ACHN: 13.79 (+0.30), CNAT: 7.11 (-0.04), MRK: 58.97 (-0.57), RGLS: 17.43 (-0.31), ABBV: 63.75 (+0.12), BMY: 57.84 (+0.04), ENTA: 43.97 (+0.75)

AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 9:07AM CST

JNJ: 108.26 (-0.81), GILD: 101.99 (-2.21), ACHN: 13.79 (+0.30), CNAT: 7.11 (-0.04), MRK: 58.97 (-0.57), RGLS: 17.43 (-0.31), ABBV: 63.75 (+0.12), BMY: 57.84 (+0.04), ENTA: 43.97 (+0.75)

Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:37AM CST

JNJ: 108.26 (-0.81), GILD: 101.99 (-2.21), ACHN: 13.79 (+0.30), CNAT: 7.11 (-0.04), MRK: 58.97 (-0.57), LGND: 57.39 (-0.57), RGLS: 17.43 (-0.31), ABBV: 63.75 (+0.12), BMY: 57.84 (+0.04), ENTA: 43.97 (+0.75)

Critical Alerts For Achillion Pharmaceuticals, Celldex Therapeutics, Kandi Technologies, Illumina and Advanced Micro Devices Released By InvestorsObserver
PR Newswire - Tue Nov 11, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for ACHN, CLDX, KNDI, ILMN and AMD.
KNDI: 13.56 (+0.39), AMD: 2.64 (-0.02), ACHN: 13.79 (+0.30), CLDX: 13.79 (-0.47), ILMN: 179.95 (-5.05)

Gilead presents data from three HCV drug combo studies
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:05AM CST

JNJ: 108.26 (-0.81), GILD: 101.99 (-2.21), ACHN: 13.79 (+0.30), CNAT: 7.11 (-0.04), LGND: 57.39 (-0.57), RGLS: 17.43 (-0.31), ABBV: 63.75 (+0.12), BMY: 57.84 (+0.04), ENTA: 43.97 (+0.75)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innovent's SINTBILO® Hits Primary Endpoint in Study

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Webull Faces Class Action Suit: Key Deadlines Loom

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Novo's Semaglutide Shows Promise in MASH Study

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

MWC26 Doha: Bridging Standards for MENA's Future

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

LG's ASIL D Certification: A Game Changer in Autos

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

GlycoNex Eyes Japanese Market with Denosumab Biosimilar

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

CureGene's Evategrel Aims for Breakthrough in Stroke Care

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...